Crinetics Pharmaceuticals, Inc. (CRNX) is a publicly traded Healthcare sector company. As of May 21, 2026, CRNX trades at $36.28 with a market cap of $3.66B and a P/E ratio of -7.30. CRNX moved +3.84% today. Year to date, CRNX is -24.72%; over the trailing twelve months it is +15.62%. Its 52-week range spans $24.10 to $62.53. Analyst consensus is strong buy with an average price target of $86.00. Rallies surfaces CRNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Which politicians traded CRNX stock?
Recent politician trading activity in CRNX includes disclosures from Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
CRNX Key Metrics
Key financial metrics for CRNX
Metric
Value
Price
$36.28
Market Cap
$3.66B
P/E Ratio
-7.30
EPS
$-4.95
Dividend Yield
0.00%
52-Week High
$62.53
52-Week Low
$24.10
Volume
581.00K
Avg Volume
0
Revenue (TTM)
$7.70M
Net Income
$-465.32M
Gross Margin
86.02%
Congressional Trades in CRNX
Josh Gottheimer purchase CRNX on Sep 25, 2024 (amount: $15.00K) for Joint.
Recent politician trading activity in CRNX includes disclosures from Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in CRNX?
Yes. Rallies tracks politician and congressional stock disclosures for CRNX, including reported purchases, sales, dates, owners, and trade amounts when available.
Is CRNX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for CRNX. It does not provide personalized investment advice.
